27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Bristol-Myers Squibb Co (NYSE: BMY) unexpectedly announced the failure of the CheckMate-026 trial in non-small cell lung cancer [NSCLC]. While this development means that Merck & Co., Inc. (NYSE: MRK) would likely dominate the 1st line NSCLC market for patients with PDL1 high expressing tumors in the near term, the success could be short-lived, Citi's Andrew Baum said in a report.
Analyst Andrew Baum maintained a Neutral rating on Merck, with a price target of $65. He added that the new EPS estimates for 2017 and 2018, at $3.81 and $4.39, were now 5 percent higher than the pre-Friday consensus expectations.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Short-Lived Success
Baum commented that Merck's EPS gains would likely be "relatively short lived" due to the expected positive data from AstraZeneca Plc's (NYSE: AZN) MYSTIC trial, scheduled for March 2017, and Bristol-Myers Squibb's CHECKMATE 227 trial, expected in August 2017. On account of these, the latest development would have only a modest impact on Merck's long-term EPS.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.